[ Business | US Market | Industry | IPO | S&P | International | PRNews | BizWire | Finance Home ]
---------------------------------------
Thursday April 23, 8:21 am Eastern TimeCompany Press ReleaseSOURCE: Biolase Technology, Inc.BIOLASE Technology, Inc. Adds Prominent Industry Veteran, Al Diaz As Vice President of Operations
SAN CLEMENTE, Calif., April 23 /PRNewswire/ -- BIOLASE TECHNOLOGY, INC. (Nasdaq: BLTI - news), a provider of laser-based advanced cosmetic, aesthetic, dental and surgical products, today announced the appointment of industry veteran Al Diaz as its Vice President of Operations.
Mr. Diaz has more than eighteen years of experience in medical equipment manufacturing and product development including the last two years where he was Vice President of Operations for Biomedical Division of Sorin Biomedica, S.p.A., an international leader in the manufacturing of cardiovascular implants with annual sales of approximately $500 million. Mr. Diaz's tenure at Sorin Biomedica was highlighted by the development of a Quality System to comply with FDA, ISO 9000 and CE Mark requirements. Prior to Sorin Biomedica, Mr. Diaz served as (i) a Director of Manufacturing, for the cardiovascular group of Baxter Health Care Corporation, a world leader in the manufacturing and distribution of health-care products, (ii) Director of Operations for Laerdal Medical, Inc., a manufacturer of external portable defibrillators, and (iii), Vice President of operations of Advanced Interventional Systems, Inc., (''AIS''), a former manufacturer of Eximer laser systems, prior to the sale of AIS to a Colorado-based laser manufacturer.
Donald A. La Point, BIOLASE President and CEO stated, ''Mr. Diaz's experience in production and manufacturing will contribute significantly to improvements in production efficiency and streamline our operations. He has extensive experience in the laser fiber industry and is expected to make a significant impact in our manufacturing cost reductions, as well as quality control and procedure implementation.''
Federico Pignatelli, BIOLASE Chairman of the Board stated, ''We are very pleased to have Mr. Diaz join our executive management team as we are rolling out our laser based products. In addition to using his quality control and ISO 9000 experience to comply with FDA requirements, we will count on his extensive background in laser fibers to execute the manufacturing and delivery of our products.''
BIOLASE Technology, Inc. manufactures and markets advanced cosmetic, aesthetic, dental and surgical products, including laser systems, HydroKinetic surgical cutting systems, and develops specialized biomaterials for dentistry and other medical specialties. The Company's products incorporate patented and patent-pending technologies that permit achievement of unique results.
The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 10-KSB and 10Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE: Biolase Technology, Inc.
---------------------------------------
More Quotes and News:Biolase Technology Inc (Nasdaq:BLTI - news)Related News Categories: medical/pharmaceutical
---------------------------------------
Help
---------------------------------------
Copyright c 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
See our Important Disclaimers and Legal Information.
Questions or Comments? |
